17.82 USD
+0.99 (+5.88%)
Overall ATRA gets a fundamental rating of 4 out of 10. We evaluated ATRA against 531 industry peers in the Biotechnology industry. While ATRA is still in line with the averages on profitability rating, there are concerns on its financial health. ATRA is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ATRA was profitable.
ATRA had a negative operating cash flow in the past year.
In the past 5 years ATRA always reported negative net income.
In the past 5 years ATRA always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 77.57%, ATRA belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
The Return On Invested Capital of ATRA (271.93%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.57% | ||
| ROE | N/A | ||
| ROIC | 271.93% |
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ATRA (15.40%) is better than 92.09% of its industry peers.
ATRA has a better Operating Margin (27.44%) than 96.05% of its industry peers.
The Gross Margin of ATRA (81.63%) is better than 85.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.44% | ||
| PM (TTM) | 15.4% | ||
| GM | 81.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATRA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ATRA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ATRA has been reduced compared to 5 years ago.
ATRA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -82.91, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
ATRA has a worse Altman-Z score (-82.91) than 95.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -82.91 |
ROIC/WACC35.5
WACC7.66%
2.3 Liquidity
ATRA has a Current Ratio of 1.02. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
ATRA's Current ratio of 1.02 is on the low side compared to the rest of the industry. ATRA is outperformed by 88.32% of its industry peers.
ATRA has a Quick Ratio of 1.02. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
ATRA has a Quick ratio of 1.02. This is amonst the worse of the industry: ATRA underperforms 87.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 108.46% over the past year.
Looking at the last year, ATRA shows a very strong growth in Revenue. The Revenue has grown by 51.27%.
Measured over the past years, ATRA shows a very strong growth in Revenue. The Revenue has been growing by 85.07% on average per year.
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
3.2 Future
ATRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.24% yearly.
The Revenue is expected to grow by 5.91% on average over the next years.
EPS Next Y116.48%
EPS Next 2Y40.66%
EPS Next 3Y20.11%
EPS Next 5Y18.24%
Revenue Next Year5.14%
Revenue Next 2Y-29.08%
Revenue Next 3Y-39.56%
Revenue Next 5Y5.91%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.17 indicates a reasonable valuation of ATRA.
Based on the Price/Earnings ratio, ATRA is valued cheaper than 97.93% of the companies in the same industry.
When comparing the Price/Earnings ratio of ATRA to the average of the S&P500 Index (26.76), we can say ATRA is valued rather cheaply.
ATRA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.17 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ATRA indicates a rather cheap valuation: ATRA is cheaper than 99.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.31 |
4.3 Compensation for Growth
ATRA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ATRA's earnings are expected to grow with 20.11% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y40.66%
EPS Next 3Y20.11%
5. Dividend
5.1 Amount
ATRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ATRA (12/11/2025, 8:20:25 PM)
17.82
+0.99 (+5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.74%
Inst Owner Change4.38%
Ins Owners1.66%
Ins Owner Change0.53%
Market Cap128.48M
Revenue(TTM)151.93M
Net Income(TTM)23.40M
Analysts80
Price Target17.34 (-2.69%)
Short Float %3.09%
Short Ratio2.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.01%
Min EPS beat(2)63.52%
Max EPS beat(2)140.49%
EPS beat(4)4
Avg EPS beat(4)136.18%
Min EPS beat(4)63.52%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)49.96%
EPS beat(12)7
Avg EPS beat(12)23.63%
EPS beat(16)9
Avg EPS beat(16)20.25%
Revenue beat(2)2
Avg Revenue beat(2)138.29%
Min Revenue beat(2)134.43%
Max Revenue beat(2)142.15%
Revenue beat(4)4
Avg Revenue beat(4)485.59%
Min Revenue beat(4)67.7%
Max Revenue beat(4)1598.08%
Revenue beat(8)6
Avg Revenue beat(8)233.67%
Revenue beat(12)6
Avg Revenue beat(12)128.56%
Revenue beat(16)8
Avg Revenue beat(16)133.26%
PT rev (1m)3.03%
PT rev (3m)3.03%
EPS NQ rev (1m)26.25%
EPS NQ rev (3m)22.42%
EPS NY rev (1m)34.73%
EPS NY rev (3m)298.39%
Revenue NQ rev (1m)40.97%
Revenue NQ rev (3m)72.36%
Revenue NY rev (1m)1.77%
Revenue NY rev (3m)2.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.17 | ||
| Fwd PE | N/A | ||
| P/S | 0.85 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.31 |
EPS(TTM)2.18
EY12.23%
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-9.68
FCFYN/A
OCF(TTM)-9.67
OCFYN/A
SpS21.07
BVpS-5.08
TBVpS-5.08
PEG (NY)0.07
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.57% | ||
| ROE | N/A | ||
| ROCE | 344.22% | ||
| ROIC | 271.93% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 27.44% | ||
| PM (TTM) | 15.4% | ||
| GM | 81.63% | ||
| FCFM | N/A |
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover5.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.71 | ||
| Cap/Depr | 2.84% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | 116.11 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -82.91 |
F-Score4
WACC7.66%
ROIC/WACC35.5
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
EPS Next Y116.48%
EPS Next 2Y40.66%
EPS Next 3Y20.11%
EPS Next 5Y18.24%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
Revenue Next Year5.14%
Revenue Next 2Y-29.08%
Revenue Next 3Y-39.56%
Revenue Next 5Y5.91%
EBIT growth 1Y134.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.44%
EBIT Next 3Y17.04%
EBIT Next 5Y-3.99%
FCF growth 1Y65.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.05%
OCF growth 3YN/A
OCF growth 5YN/A
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
Can you provide the ChartMill fundamental rating for ATARA BIOTHERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to ATRA.
What is the valuation status for ATRA stock?
ChartMill assigns a valuation rating of 5 / 10 to ATARA BIOTHERAPEUTICS INC (ATRA). This can be considered as Fairly Valued.
How profitable is ATARA BIOTHERAPEUTICS INC (ATRA) stock?
ATARA BIOTHERAPEUTICS INC (ATRA) has a profitability rating of 4 / 10.
What are the PE and PB ratios of ATARA BIOTHERAPEUTICS INC (ATRA) stock?
The Price/Earnings (PE) ratio for ATARA BIOTHERAPEUTICS INC (ATRA) is 8.17 and the Price/Book (PB) ratio is -3.51.
What is the earnings growth outlook for ATARA BIOTHERAPEUTICS INC?
The Earnings per Share (EPS) of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 116.48% in the next year.